Vanguard Global Advisers
SANA icon

Vanguard Global Advisers’s Sana Biotechnology SANA Stock Holding History

Vanguard Global Advisers’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Hold
60,325
– – ﹤0.01% 2484
2026
Q1 		$174K Buy
+60,325
New +$238K ﹤0.01% 2501

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Vanguard Global Advisers's SANA Position: Q2 2026 in Review

Vanguard Global Advisers held its Sana Biotechnology (SANA) position steady in Q2 2026 at 60,325 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #2484.

Vanguard Global Advisers first reported a position in SANA in Q1 2026 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Vanguard Global Advisers held 60,325 shares of Sana Biotechnology worth $211K as of Q2 2026.
  • Vanguard Global Advisers left its Sana Biotechnology share count unchanged in Q2 2026.
  • Sana Biotechnology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2484 holding.
  • Vanguard Global Advisers first reported a position in Sana Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.